Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:28:53.429Z.
Calculation as of: 2026-10-06T21:28:53.429Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e4092e053989caac2e99517ddb979985c78622fc494c6088febce458b2dbbcab
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2022-03-29.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
EV/EBITDA RATIO AVG TTM
N/A
EV/EBITDA RATIO AVG 3Y
N/A
EV/EBITDA RATIO AVG 5Y
N/A
EV/EBITDA RATIO AVG 10Y
N/A
EV/EBITDA RATIO AVG 15Y
N/A
EV/EBITDA RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SAB Biotherapeutics, Inc.
Market Cap
$266.59M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$265.78M
EV/EBITDA Ratio
N/A
TTM Avg
10.21x
3Y Avg
10.21x
5Y Avg
10.68x
Market Cap
$262.92M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$270.80M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.43M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$271.81M
EV/EBITDA Ratio
N/A
TTM Avg
15.28x
3Y Avg
21.84x
5Y Avg
24.53x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | $266.59M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $266.92M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | N/A | 10.21x | 10.21x | 10.68x |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | N/A | N/A | N/A | N/A |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $270.80M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | N/A | N/A | N/A | N/A |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $271.81M | N/A | 15.28x | 21.84x | 24.53x |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | N/A | 2.41x | 3817.71x | 2177.76x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBITDA RATIO |
|---|---|
| 2022-03-29 | 25.79x |
| 2022-03-28 | 24.00x |
| 2022-03-25 | 22.21x |
| 2022-03-24 | 23.28x |
| 2022-03-23 | 25.31x |
| 2022-03-22 | 23.88x |
| 2022-03-21 | 21.37x |
| 2022-03-18 | 22.81x |
| 2022-03-17 | 20.90x |
| 2022-03-16 | 20.18x |
| 2022-03-15 | 20.66x |
| 2022-03-14 | 20.30x |
| 2022-03-11 | 22.33x |
| 2022-03-10 | 24.48x |
| 2022-03-09 | 26.15x |
| 2022-03-08 | 26.27x |
| 2022-03-07 | 26.51x |
| 2022-03-04 | 29.02x |
| 2022-03-03 | 31.17x |
| 2022-03-02 | 31.88x |
| 2022-03-01 | 53.74x |
| 2022-02-28 | 58.16x |
| 2022-02-25 | 58.28x |
| 2022-02-24 | 59.71x |
| 2022-02-23 | 58.52x |
| 2022-02-22 | 61.14x |
| 2022-02-18 | 58.52x |
| 2022-02-17 | 61.14x |
| 2022-02-16 | 63.29x |
| 2022-02-15 | 63.29x |
| 2022-02-14 | 60.07x |
| 2022-02-11 | 66.04x |
| 2022-02-10 | 65.20x |
| 2022-02-09 | 62.22x |
| 2022-02-08 | 59.83x |
| 2022-02-07 | 63.05x |
| 2022-02-04 | 66.76x |
| 2022-02-03 | 61.38x |
| 2022-02-02 | 64.25x |
| 2022-02-01 | 68.67x |
| 2022-01-31 | 68.31x |
| 2022-01-28 | 60.78x |
| 2022-01-27 | 56.01x |
| 2022-01-26 | 61.62x |
| 2022-01-25 | 70.10x |
| 2022-01-24 | 71.65x |
| 2022-01-21 | 64.37x |
| 2022-01-20 | 68.43x |
| 2022-01-19 | 67.47x |
| 2022-01-18 | 69.02x |
| 2022-01-14 | 79.53x |
| 2022-01-13 | 83.95x |
| 2022-01-12 | 89.21x |
| 2022-01-11 | 90.52x |
| 2022-01-10 | 90.28x |
| 2022-01-07 | 86.94x |
| 2022-01-06 | 90.52x |
| 2022-01-05 | 91.96x |
| 2022-01-04 | 94.82x |
| 2022-01-03 | 100.43x |
| 2021-12-31 | 92.19x |
| 2021-12-30 | 93.99x |
| 2021-12-29 | 102.70x |
| 2021-12-28 | 104.73x |
| 2021-12-27 | 106.76x |
| 2021-12-23 | 103.42x |
| 2021-12-22 | 102.23x |
| 2021-12-21 | 100.91x |
| 2021-12-20 | 101.51x |
| 2021-12-17 | 103.78x |
| 2021-12-16 | 107.96x |
| 2021-12-15 | 115.36x |
| 2021-12-14 | 105.81x |
| 2021-12-13 | 110.23x |
| 2021-12-10 | 107.72x |
| 2021-12-09 | 107.12x |
| 2021-12-08 | 107.36x |
| 2021-12-07 | 105.69x |
| 2021-12-06 | 103.66x |
| 2021-12-03 | 116.92x |
| 2021-12-02 | 122.17x |
| 2021-12-01 | 133.16x |
| 2021-11-30 | 128.98x |
| 2021-11-29 | 120.98x |
| 2021-11-26 | 124.32x |
| 2021-11-24 | 105.21x |
| 2021-11-23 | 101.63x |
